14g2a.zeta chimeric receptor transduced autologous ebv specific cytotoxic t-lymphocytes
Cell therapyexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2003 (NCT00085930)
Timeline
2000s
- Jan 1, 2003
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Human herpesvirus 4Immunity, passive
Human herpesvirus 4 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 14g2a.zeta chimeric receptor transduced autologous ebv specific cytotoxic t-lymphocytes
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00085930 | Phase 1 | Apr 1, 2003 | Baylor University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Baylor University | Academic/Hospital | 1 | 1 | 1 | 2003 |
1 organizations
Page 1 / 1